
Jean-Philippe Guilloux

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7651496/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Optogenetic activation of granule cells in the dorsal dentate gyrus enhances dopaminergic neurotransmission in the Nucleus Accumbens. Neuroscience Research, 2018, 134, 56-60.	1.0	11
2	Vortioxetine Improves Context Discrimination in Mice Through a Neurogenesis Independent Mechanism. Frontiers in Pharmacology, 2018, 9, 204.	1.6	8
3	S 38093, a histamine H3 antagonist/inverse agonist, promotes hippocampal neurogenesis and improves context discrimination task in aged mice. Scientific Reports, 2017, 7, 42946.	1.6	29
4	Chronic corticosterone administration effects on behavioral emotionality in female c57bl6 mice Experimental and Clinical Psychopharmacology, 2017, 25, 94-104.	1.3	45
5	S 47445 Produces Antidepressant- and Anxiolytic-Like Effects through Neurogenesis Dependent and Independent Mechanisms. Frontiers in Pharmacology, 2017, 8, 462.	1.6	47
6	Differential Peripheral Proteomic Biosignature of Fluoxetine Response in a Mouse Model of Anxiety/Depression. Frontiers in Cellular Neuroscience, 2017, 11, 237.	1.8	29
7	Cognitive Dysfunction in Major Depressive Disorder. A Translational Review in Animal Models of the Disease. Pharmaceuticals, 2016, 9, 9.	1.7	71
8	Alterations in alpha5* nicotinic acetylcholine receptors result in midbrain- and hippocampus-dependent behavioural and neural impairments. Psychopharmacology, 2016, 233, 3297-3314.	1.5	18
9	Anxiety- and Depression-Like States Lead to Pronounced Olfactory Deficits and Impaired Adult Neurogenesis in Mice. Journal of Neuroscience, 2016, 36, 518-531.	1.7	94
10	The role of CSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature. L'Encephale, 2016, 42, 156-164.	0.3	44
11	Genetic dysfunction of serotonin 2A receptor hampers response to antidepressant drugs: A translational approach. Neuropharmacology, 2016, 105, 142-153.	2.0	32
12	Chronic 5-HT4 receptor agonist treatment restores learning and memory deficits in a neuroendocrine mouse model of anxiety/depression. Neuroscience Letters, 2016, 616, 197-203.	1.0	23
13	Molecular and Genetic Characterization of Depression: Overlap with Other Psychiatric Disorders and Aging. Molecular Neuropsychiatry, 2015, 1, 1-12.	3.0	56
14	Testing the Predictive Value of Peripheral Gene Expression for Nonremission Following Citalopram Treatment for Major Depression. Neuropsychopharmacology, 2015, 40, 701-710.	2.8	58
15	Brain-derived neurotrophic factor Val66Met polymorphism and 6-month antidepressant remission in depressed Caucasian patients. Journal of Affective Disorders, 2015, 175, 233-240.	2.0	44
16	Vortioxetine for the treatment of major depressive disorder. Expert Review of Clinical Pharmacology, 2014, 7, 731-745.	1.3	22
17	Learning and memory impairments in a neuroendocrine mouse model of anxiety/depression. Frontiers in Behavioral Neuroscience, 2014, 8, 136.	1.0	96
18	NREM sleep hypersomnia and reduced sleep/wake continuity in a neuroendocrine mouse model of anxiety/depression based on chronic corticosterone administration. Neuroscience, 2014, 274, 357-368.	1.1	19

#	Article	IF	CITATIONS
19	Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. Neuropharmacology, 2013, 73, 147-159.	2.0	108
20	Anticipated Brain Molecular Aging in Major Depression. American Journal of Geriatric Psychiatry, 2013, 21, 450-460.	0.6	53
21	Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety. International Journal of Neuropsychopharmacology, 2012, 15, 321-335.	1.0	91
22	Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major depression. Molecular Psychiatry, 2012, 17, 1130-1142.	4.1	311
23	Brain-Derived Neurotrophic Factor Signaling and Subgenual Anterior Cingulate Cortex Dysfunction in Major Depressive Disorder. American Journal of Psychiatry, 2012, 169, 1194-1202.	4.0	221
24	Ventral hippocampal molecular pathways and impaired neurogenesis associated with 5-HT1A and 5-HT1B receptors disruption in mice. Neuroscience Letters, 2012, 521, 20-25.	1.0	34
25	Alpha7-nicotinic receptors modulate nicotine-induced reinforcement and extracellular dopamine outflow in the mesolimbic system in mice. Psychopharmacology, 2012, 220, 1-14.	1.5	49
26	Anticipated Brain Molecular Aging in Major Depression. American Journal of Geriatric Psychiatry, 2012, , 1.	0.6	2
27	Characterization of 5-HT1A/1Bâ^'/â^' mice: An animal model sensitive to anxiolytic treatments. Neuropharmacology, 2011, 61, 478-488.	2.0	38
28	Integrated behavioral z-scoring increases the sensitivity and reliability of behavioral phenotyping in mice: Relevance to emotionality and sex. Journal of Neuroscience Methods, 2011, 197, 21-31.	1.3	242
29	A longitudinal study of 5-HT outflow during chronic fluoxetine treatment using a new technique of chronic microdialysis in a highly emotional mouse strain. European Journal of Pharmacology, 2010, 628, 83-90.	1.7	55
30	Network analysis of positional candidate genes of schizophrenia highlights…more than… myelin-related pathways. Molecular Psychiatry, 2010, 15, 786-788.	4.1	7
31	Cyclotraxin-B, the First Highly Potent and Selective TrkB Inhibitor, Has Anxiolytic Properties in Mice. PLoS ONE, 2010, 5, e9777.	1.1	78
32	Altered Gene Synchrony Suggests a Combined Hormone-Mediated Dysregulated State in Major Depression. PLoS ONE, 2010, 5, e9970.	1.1	38
33	Striatal GPR88 expression is confined to the whole projection neuron population and is regulated by dopaminergic and glutamatergic afferents. European Journal of Neuroscience, 2009, 30, 397-414.	1.2	78
34	Interest of using genetically manipulated mice as models of depression to evaluate antidepressant drugs activity: a review. Fundamental and Clinical Pharmacology, 2009, 23, 23-42.	1.0	36
35	Neurogenesis-Dependent and -Independent Effects of Fluoxetine in an Animal Model of Anxiety/Depression. Neuron, 2009, 62, 479-493.	3.8	1,080
36	Consequences of changes in BDNF levels on serotonin neurotransmission, 5-HT transporter expression and function: Studies in adult mice hippocampus. Pharmacology Biochemistry and Behavior, 2008, 90, 174-183.	1.3	50

#	Article	IF	CITATIONS
37	A randomised trial of three counselling strategies for lifestyle changes in patients with hypercholesterolemia treated with ezetimibe on top of statin therapy (TWICE). Archives of Cardiovascular Diseases, 2008, 101, 723-735.	0.7	6
38	Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice. Neuropharmacology, 2008, 55, 1006-1014.	2.0	136
39	Substance P Neurokinin 1 Receptor Activation within the Dorsal Raphe Nucleus Controls Serotonin Release in the Mouse Frontal Cortex. Molecular Pharmacology, 2007, 72, 1411-1418.	1.0	36
40	Targeted In Vivo Expression of Nicotinic Acetylcholine Receptors in Mouse Brain Using Lentiviral Expression Vectors. Journal of Molecular Neuroscience, 2006, 30, 105-106.	1.1	10
41	Blockade of 5-HT1A Receptors by (±)-Pindolol Potentiates Cortical 5-HT Outflow, but not Antidepressant-Like Activity of Paroxetine: Microdialysis and Behavioral Approaches in 5-HT1A Receptor Knockout Mice. Neuropsychopharmacology, 2006, 31, 2162-2172.	2.8	63
42	Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature, 2005, 436, 103-107.	13.7	548
43	Rapid and precise method to locate microdialysis probe implantation in the rodent brain. Journal of Neuroscience Methods, 2004, 140, 53-57.	1.3	49
44	Blockade of substance P (neurokinin 1) receptors enhances extracellular serotonin when combined with a selective serotonin reuptake inhibitor: an in vivo microdialysis study in mice. Journal of Neurochemistry, 2004, 89, 54-63.	2.1	60